Shell Asset Management Co. held its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,612 shares of the company’s stock at the end of the second quarter. Shell Asset Management Co.’s holdings in Neurocrine Biosciences were worth $534,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its stake in Neurocrine Biosciences by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 165,953 shares of the company’s stock valued at $6,422,000 after buying an additional 4,428 shares during the last quarter. Teachers Advisors LLC increased its stake in Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock valued at $3,030,000 after buying an additional 4,668 shares during the last quarter. Capstone Asset Management Co. acquired a new stake in Neurocrine Biosciences during the first quarter valued at about $214,000. Quantitative Systematic Strategies LLC acquired a new stake in Neurocrine Biosciences during the first quarter valued at about $261,000. Finally, Columbus Circle Investors increased its stake in Neurocrine Biosciences by 33.3% in the first quarter. Columbus Circle Investors now owns 207,699 shares of the company’s stock valued at $8,993,000 after buying an additional 51,872 shares during the last quarter. Institutional investors own 95.87% of the company’s stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 54.07 on Monday. The stock’s market capitalization is $4.77 billion. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $55.38. The firm’s 50-day moving average is $48.53 and its 200-day moving average is $46.79.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share. Analysts predict that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current fiscal year.
Several analysts recently issued reports on the stock. Cowen and Company reissued an “outperform” rating and issued a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, May 24th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. BMO Capital Markets lifted their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. Finally, Oppenheimer Holdings Inc. set a $70.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, May 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $68.25.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 22,500 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $50.00, for a total value of $1,125,000.00. Following the transaction, the insider now directly owns 154,601 shares of the company’s stock, valued at $7,730,050. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Malcolm Lloyd-Smith sold 9,960 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the completion of the transaction, the insider now directly owns 17,997 shares in the company, valued at $965,179.11. The disclosure for this sale can be found here. Insiders have sold 51,194 shares of company stock worth $2,629,755 over the last ninety days. 4.80% of the stock is currently owned by insiders.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.